ArticleScientific reports2025
Gut microbiota constituents may affect hypertrophic scarring risk through interaction with specific immune cells in a two-step, two-sample Mendelian randomization study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Targeting the gut to heal the skin: probiotic supplementation reduces wound infection risk and clinical burden in critically ill patients-a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- The impact of obesity-related systemic inflammation on the efficacy, toxicity, and biomarkers of immune checkpoint inhibitors in lung cancer: from mechanisms to clinical management.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hypertrophic scars (HS), classified as abnormal scarring, result from an overactive tissue response during wound healing following dermal trauma. Nonetheless, the precise mechanistic pathway underlying its occurrence remains elusive. The principal aim of this study is to elucidate the causal relationship among gut microbiota (GM), immune cell function, and hypertrophic scarring in a European demographic. Leveraging the genome-wide association analysis (GWAS) database, we conducted a two-sample Mendelian randomization (MR) study on gut microbiota (GM), immune cells, and HS. To ascertain the causality between GM, immune cells, and HS, we utilized the inverse variance weighted (IVW) method while employing multiple approaches to negate the effects of pleiotropy and heterogeneity. Furthermore, we quantitatively evaluated the influences of immune cells-mediated GM on hypertrophic scar through a two-step MR analysis. The two-sample MR analysis demonstrated a potential causality between 5 genera of gut microbiotas and 23 immune cell traits with respect to hypertrophic scarring. Further, our results showed that the causal pathway from the genus Subdoligranulum to hypertrophic scar (HS) was mediated by B cell-activating factor receptor (BAFF-R) on CD20- CD38- B cell, with a beta value of 0.034 (95% CI [0.002, 0.066]; P = 0.004), contributing to 7.60% of the total effect of Subdoligranulum on HS. Similarly, CD24 on IgD + CD38 + B cell exhibited a causal impact in the pathway from genus Coprococcus 1 to HS, with a beta value of -0.015 (95% CI [-0.029, -0.001]; P = 0.023), constituting 6.70% of the total effect of Coprococcus 1 on HS. Additionally, the CD8 + T cell %T cell mediated the causal pathway from the genus Adlercreutzia to HS with a beta value of 0.075 (95% CI [0.017, 0.133]; P = 0.024), contributing to 10.10% of the total effect of Adlercreutzia on HS. Our study indicates that the development of hypertrophic scars might be influenced by specific gut microbiota and immune cells. We highlight the possible role of two distinct immune cell genotypes as mediators in this relationship. However, most statistical significance of these findings was not maintained after FDR correction, suggesting our results should be viewed as preliminary and interpreted with caution. Further research is needed to confirm these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.